Background: Erlotinib is approved as treatment for metastatic non-small-cell lung cancer
(NSCLC), following failure of initial therapy. Studies to define patients that derive maximal …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …

Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Background: A randomized trial carried out by Shepherd et al. in patients with advanced or
metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over …

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …

Background: Erlotinib, docetaxel and pemetrexed are all approved in the second-line setting
for patients with advanced NSCLC who progress following first-line platinum doublet …

Methods An open labeled, expanded access program (EAP) was conducted on 44
pathologically confirmed advanced NSCLC patients who had received at least one regimen …

Introduction The purpose of this study was to describe treatment use patterns and outcomes
with single-agent erlotinib among patients with advanced Non–Small-cell lung cancer …